Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.52 USD | 0.00% | 0.00% | -30.99% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.99% | 189M | D | ||
+5.31% | 70.44B | A | ||
+10.97% | 8.94B | A- | ||
-16.83% | 4.75B | A- | ||
+43.48% | 4.5B | - | ||
+3.20% | 3.85B | B- | ||
-21.36% | 2.34B | C- | ||
-29.67% | 2.2B | - | ||
+8.38% | 1.96B | - | - | |
+3.90% | 1.65B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZVRA Stock
- Ratings Zevra Therapeutics, Inc.